多重肿瘤相关自身抗体血液检测用于结直肠癌检测的研发
本研究用ELISA检测192份血清(92例结直肠癌和100例匹配对照)对12种肿瘤相关抗原的自身抗体,评估个体及联合自身抗体标志物的诊断价值。四种抗体组合(抗SLP2、p53、SEC61B和PLSCR1)总体敏感性64.1%、特异性80%,加入癌胚抗原(CEA)后特异性升至83.7%。该四抗体组合对早期和晚期结直肠癌的敏感性分别为66.7%和62%,加入CEA后分别升至88.3%和84%。
要点
- 四抗体组合(SLP2、p53、SEC61B、PLSCR1)诊断CRC总体敏感性64.1%、特异性80%。
- 加入CEA后特异性升至83.7%,早期和晚期敏感性分别升至88.3%和84%。
- 联合自身抗体标志物较单个标志物能更好区分肿瘤与正常血清。
核心结论
- 四种抗体组合是检测结直肠癌的有前景的诊断生物标志物。
研究设计与样本
- 共检测192份血清样本(92例结直肠癌和100例匹配对照),用ELISA检测12种肿瘤相关抗原的自身抗体。
- 检测的12种肿瘤相关抗原为RPH3AL、RPL36、SLP2、p53、survivin、ANAxA4、SEC61B、CCCAP、NYCO16、NMDAR、PLSCR1和HDAC5。
- 分析了单个和联合自身抗体标志物。
主要发现
- 与单个自身抗体标志物相比,肿瘤相关抗原组合能更好区分肿瘤血清与正常血清。
- 所选四抗体组合(抗SLP2、p53、SEC61B和PLSCR1)总体敏感性为64.1%,特异性为80%。
- 加入癌胚抗原(CEA)检测后,特异性增至83.7%。
- 四抗体组合对早期和晚期结直肠癌的敏感性分别为66.7%和62%,加入CEA后分别增至88.3%和84%。
关键数值与推荐
- 四抗体组合总体敏感性64.1%、特异性80%;加入CEA后特异性83.7%。
- 四抗体组合对早期和晚期CRC敏感性分别为66.7%和62%;加入CEA后分别为88.3%和84%。
临床怎么用
- 该四抗体组合可作为结直肠癌检测的候选血液标志物,联合CEA可提高特异性及早期和晚期敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colorectal cancer (CRC) is one of the most common malignancies worldwide, and early diagnosis is vital to improving prognoses. We explored the diagnostic potential of a multiplex autoantibody panel as a biomarker for the detection of CRC by ELISA. METHODS: In total, 192 serum samples (92 CRC and 100 matched controls) were tested against a panel of 12 tumor-associated antigens (TAAs): RPH3AL, RPL36, SLP2, p53, survivin, ANAXA4, SEC61B, CCCAP, NYCO16, NMDAR, PLSCR1, and HDAC5. Individual and combined autoantibody signatures were examined. RESULTS: Compared to individual autoantibody markers, the combinations of TAAs provided better discrimination between tumorous and normal sera. The overall sensitivity of a selected panel of four antibodies (anti-SLP2, -p53, -SEC61B, and -PLSCR1) was 64.1%, with a specificity of 80% that increased to 83.7% when carcinoembryonic antigen (CEA) measurement was added. Furthermore, the sensitivity of the panel of four antibodies for early and advanced stages of CRC was 66.7% and 62%, increasing to 88.3% and 84%, respectively, when CEA was added. CONCLUSIONS: We identified a panel of four antibodies as a promising diagnostic biomarker for the detection of CRC.
引用
- Fan CW, Kuo YB, Lin GP, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer. Clin Chim Acta. 2017. PMID: 29074220. doi:10.1016/j.cca.2017.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。